TY - JOUR
T1 - High Expression of the Tumor Suppressor Protein ITIH5 in Cholangiocarcinomas Correlates with a Favorable Prognosis
AU - Dreyer, Verena J.
AU - Shi, Jia Xin
AU - Rose, Michael
AU - Onyuro, Maureen T.
AU - Steib, Florian
AU - Hilgers, Lars
AU - Seillier, Lancelot
AU - Dietrich, Jana
AU - Riese, Janik
AU - Meurer, Steffen K.
AU - Weiskirchen, Ralf
AU - Neumann, Ulf
AU - Heij, Lara
AU - Luedde, Tom
AU - Loosen, Sven H.
AU - Lurje, Isabella
AU - Lurje, Georg
AU - Gaisa, Nadine T.
AU - Jonigk, Danny
AU - Bednarsch, Jan
AU - Dahl, Edgar
AU - Brüchle, Nadina Ortiz
N1 - Publisher Copyright: © 2024 by the authors.
PY - 2024/11
Y1 - 2024/11
N2 - Inter-alpha-trypsin inhibitor-5 (ITIH5), a class II tumor suppressor gene, encodes a protein that is lost during tumor progression in many solid cancers. Unexpectedly, however, ITIH5 is significantly upregulated in cholangiocarcinoma (CCA), making it a potential liquid biopsy marker for early CCA detection, as recently shown. Indeed, CCA is the first tumor entity described in which ITIH5 is upregulated rather than downregulated in the tumor compared to normal tissue. In our study, we demonstrate that CCAs with abundant ITIH5 protein expression have favorable survival, a low UICC stage and the absence of perineural invasion. The re-expression of ITIH5 impairs the colony growth of cholangiocarcinoma cell lines. Although ITIH5 is upregulated in the tumor, it retains its tumor-suppressive function in CCA, similar to other tumor entities such as breast cancer and pancreatic cancer, where it is downregulated. Thus, ITIH5 may have both diagnostic and prognostic biomarker potential in CCA. The mechanisms of ITIH5 upregulation, particularly in intrahepatic CCAs, during oncogenic transformation remain unclear, but their elucidation could improve future CCA therapies.
AB - Inter-alpha-trypsin inhibitor-5 (ITIH5), a class II tumor suppressor gene, encodes a protein that is lost during tumor progression in many solid cancers. Unexpectedly, however, ITIH5 is significantly upregulated in cholangiocarcinoma (CCA), making it a potential liquid biopsy marker for early CCA detection, as recently shown. Indeed, CCA is the first tumor entity described in which ITIH5 is upregulated rather than downregulated in the tumor compared to normal tissue. In our study, we demonstrate that CCAs with abundant ITIH5 protein expression have favorable survival, a low UICC stage and the absence of perineural invasion. The re-expression of ITIH5 impairs the colony growth of cholangiocarcinoma cell lines. Although ITIH5 is upregulated in the tumor, it retains its tumor-suppressive function in CCA, similar to other tumor entities such as breast cancer and pancreatic cancer, where it is downregulated. Thus, ITIH5 may have both diagnostic and prognostic biomarker potential in CCA. The mechanisms of ITIH5 upregulation, particularly in intrahepatic CCAs, during oncogenic transformation remain unclear, but their elucidation could improve future CCA therapies.
UR - https://www.scopus.com/pages/publications/85208379681
U2 - 10.3390/cancers16213647
DO - 10.3390/cancers16213647
M3 - Article
C2 - 39518085
AN - SCOPUS:85208379681
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 21
M1 - 3647
ER -